Why Novavax Stock Is Moving Today
Novavax, Inc. (NASDAQ: NVAX) shares are trading higher by 9.8% at $230.25 Monday morning after the company announced positive Phase 3 trial results for its COVID-19 vaccine.
iTeos Therapeutics Stock Surges On $2.1B Development Pact For EOS-448 With GSK
iTeos Therapeutics (NASDAQ:ITOS) and GlaxoSmithKline plc (NYSE:GSK) have agreed to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody. Under the terms of…
Johnson & Johnson Building Case With New Patient Survival Data For Darzalex In Multiple Myeloma
Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE:JNJ), announced overall survival (OS) results from the Phase 3 MAIA study evaluating the…
Ascendis Pharma’s TransCon hGH FDA Review Pushed Backed By Three Months
The FDA has extended the ongoing review of the marketing application of Ascendis Pharma A/S’s (NASDAQ:ASND) TransCon hGH (lonapegsomatropin) for the treatment…
Sorrento, Mayo Clinic Ink Research Pact For Ipilimumab-Delivering Sofusa In Melanoma Patients
Sorrento Therapeutics Inc (NASDAQ:SRNE) entered into a research collaboration agreement with Mayo Clinic to conduct human clinical proof of concept studies…
Avenue Therapeutics Pain Management Treatment Rejected By FDA Again; Shares Drop
Avenue Therapeutics Inc (NASDAQ:ATXI) has received a second Complete Response Letter from the FDA regarding its marketing application seeking approval for…
Sorrento Therapeutics Starts Large Efficacy Trial For Intranasal COVID-19 Antibody In UK
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) signed off Sorrento Therapeutics Inc’s (NASDAQ:SRNE) Phase 2 trial evaluating COVI-DROPS in…
Long-awaited Novavax’s COVID-19 Vaccine Results Hit 90% Efficacy In Pivotal US Trial, 100% Efficacy Against Moderate, Severe Infection
Novavax Inc (NASDAQ:NVAX) has finally completed its U.S. Phase 3 trial for its protein-based COVID-19 vaccine candidate. Overall efficacy in the…
Novavax’s COVID-19 Vaccine Candidate Showed Immune Response, Protection Against Variants
Novavax Inc (NASDAQ:NVAX) announced preclinical and clinical data on its recombinant protein COVID-19 vaccine candidate, NVX-CoV2373, directed against the SARS-CoV-2 Beta…
The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs
Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves.